Who Exports Adalimumab from India — 67 Suppliers Behind a $1.2M Market
India's adalimumab export market is supplied by 67 active exporters who collectively shipped $1.2M across 223 shipments. RELIANCE LIFE SCIENCES PRIVATE LIMITED leads with a 28.3% market share, followed by ZYDUS LIFESCIENCES LIMITED and CADILA HEALTHCARE LIMITED. The top 5 suppliers together control 41.5% of total export value, reflecting a moderately competitive market structure.
Top Adalimumab Exporters from India — Ranked by Export Value
RELIANCE LIFE SCIENCES PRIVATE LIMITED is the leading adalimumab exporter from India, holding a 28.3% share of the $1.2M market across 223 shipments from 67 exporters. The top 5 suppliers — RELIANCE LIFE SCIENCES PRIVATE LIMITED, ZYDUS LIFESCIENCES LIMITED, CADILA HEALTHCARE LIMITED, PHARMA CHOICE LLP, REMEDI PHARMA DISTRIBUTORS — collectively control 41.5% of total export value, indicating a competitive market. Individual shares are: RELIANCE LIFE SCIENCES PRIVATE LIMITED (28.3%), ZYDUS LIFESCIENCES LIMITED (5.6%), CADILA HEALTHCARE LIMITED (3.1%), PHARMA CHOICE LLP (2.2%), REMEDI PHARMA DISTRIBUTORS (2.1%).
Top Adalimumab Exporters from India
Ranked by export value · 67 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | RELIANCE LIFE SCIENCES PRIVATE LIMITED ADALIMUMAB INJECTION 40MG (ADALIREL 40MGEXEMPTIA INJECTION ADALIMUMAB INJECTION40MG/ 0.8ML | $338.1K | 10 | 28.3% |
| 2 | ZYDUS LIFESCIENCES LIMITED EXEMPTIA INJECTION ADALIMUMAB INJECTION40MG/ 0.8MLEXEMPTIA 40MG INJECTIONEXEMPTIA INJECTION 1X1 PFS (ADALIMUMAB I | $66.8K | 3 | 5.6% |
| 3 | CADILA HEALTHCARE LIMITED EXEMPTIA INJECTION ADALIMUMAB INJECTION40MG/ 0.8MLEXEMPTIA 40MG INJECTIONEXEMPTIA INJECTION 1X1 PFS (ADALIMUMAB I | $37.5K | 1 | 3.1% |
| 4 | PHARMA CHOICE LLP ADALIMUMAB BULKADALIMUMAB 40 MG WITHEXEMPTIA ADALIMUMAB INJ 40MG 0 8ML | $26.7K | 4 | 2.2% |
| 5 | REMEDI PHARMA DISTRIBUTORS | $25.4K | 1 | 2.1% |
| 6 | SPECIALITY PHARMA INJ EXEMPTIA 40MG/O 8ML PFSEXEMPTIA,ADALIMUMAB 40MG, | $15.7K | 1 | 1.3% |
| 7 | PARAM CORPORATION | $14.2K | 2 | 1.2% |
| 8 | ZYPHAR'S PHARMACEUTICS PRIVATE LIMITED | $9.4K | 3 | 0.8% |
| 9 | GENEX PHARMA EXEMPTIA ADALIMUMAB INJ 40MG 0 8MLADALIREL 40MGADALIMUMAB 40MG/0.8ML INJECTION | $7.7K | 1 | 0.6% |
| 10 | NIBA HEALTHCARE PHARMACEUTICALS PRODUCTS EXEMPTIA INJ ADALIMUMAB | $7.2K | 2 | 0.6% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Adalimumab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Warning Letter (August 20 | Unknown | Unknown | Not verified | Received FDA warning letter for cGMP violations at Jarod facility. |
| Cadila Pharmaceuticals Limited | Warning Letter (November | Yes, Ethiopia facili | Unknown | Not verified | Received FDA warning letter for manufacturing practice discrepancies at Ankleshw |
| Cadila Healthcare Limited (now Zydus Lifesciences Limited) | Warning Letter (October 2 | Unknown | Unknown | Not verified | Received FDA warning letter for manufacturing issues at Moraiya facility. |
| Reliance Life Sciences Private Limited | Not Listed | Yes, as per CDSCO | Unknown | Not verified | WHO-GMP certified; no FDA warning letters found. |
| Glenmark Pharmaceuticals Limited | Warning Letter (July 2025 | Unknown | Unknown | Not verified | Received FDA warning letter in July 2025. |
| Hikal Limited | Warning Letter (August 20 | Unknown | Unknown | Not verified | Received FDA warning letter in August 2025. |
| Kenil Healthcare Private Limited | Warning Letter (June 2025 | Unknown | Unknown | Not verified | Received FDA warning letter in June 2025. |
| Shiva Analyticals Private Limited | Warning Letter (July 2025 | Unknown | Unknown | Not verified | Received FDA warning letter in July 2025. |
TransData Nexus reviewed the regulatory standing of 8 leading Adalimumab exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 0 are EU GMP compliant. 7 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Adalimumab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma City of India," contributes nearly 40% of the country's bulk drug production and hosts over 2,000 pharmaceutical companies. The city is home to major firms such as Dr. Reddy's Laboratories, Aurobindo Pharma, and Natco Pharma. The Hyderabad Pharma City project aims to further enhance the city's status as a global pharmaceutical hub.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant center for pharmaceutical formulations, accounting for 33% of India's drug manufacturing and 28% of drug exports. The region houses prominent companies like Zydus Lifesciences, Alembic Pharmaceuticals, and Cadila Healthcare. Vadodara, in particular, has become a hub for pharmaceutical industries, with many small and large pharma companies located within and nearby.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical industry, leveraging its strategic coastal location and well-developed port infrastructure. This region hosts numerous pharmaceutical companies and facilitates significant export activities, contributing to India's position as a leading exporter of pharmaceutical products worldwide.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, primarily due to favorable tax incentives and supportive government policies. This area attracts numerous pharmaceutical companies seeking cost-effective production facilities, thereby enhancing India's overall pharmaceutical manufacturing capacity.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different pharmaceutical clusters to mitigate risks associated with supply chain disruptions.
- Leverage Regional Strengths: Utilize Hyderabad for bulk drug procurement, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to the regulatory standards set by authorities such as the Central Drugs Standard Control Organisation (CDSCO) and the Directorate General of Foreign Trade (DGFT).
- Assess Export Capabilities: Evaluate suppliers' export experience, particularly to key markets like Venezuela, Sri Lanka, Nepal, Bangladesh, and the UAE, to align with existing trade patterns.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Adalimumab exporters from India
Zydus Lifesciences Limited — Zydus partners with RK Pharma for US oncology product
Zydus Lifesciences entered into an exclusive licensing and commercialization agreement with RK Pharma Inc. for a novel sterile injectable oncology supportive care product targeting the US market. Under this agreement, RK Pharma will manufacture and supply the product, while Zydus will handle the New Drug Application (NDA) submission and commercialization. The product is expected to be filed in 2026. - IMPACT: This collaboration is not directly related to Adalimumab exports but demonstrates Zydus's strategic initiatives in expanding its oncology portfolio.
Impact: This collaboration is not directly related to Adalimumab exports but demonstrates Zydus's strategic initiatives in expanding its oncology portfolio.
Common Questions — Adalimumab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which adalimumab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, RELIANCE LIFE SCIENCES PRIVATE LIMITED leads with 20 recorded shipments worth $338.1K. ZYDUS LIFESCIENCES LIMITED (22 shipments) and CADILA HEALTHCARE LIMITED (4 shipments) are also established high-volume exporters.
Q How many adalimumab manufacturers are there in India?
India has 67 active adalimumab exporters with a combined export market of $1.2M across 223 shipments to 53 countries. The top 5 suppliers hold 41.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for adalimumab from India?
Average FOB unit price: $111.11 per unit, ranging from $0.98 to $1245.35. Average shipment value: $5.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 67 verified Indian exporters of Adalimumab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 223 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 53 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
223 Verified Shipments
67 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists